Indications to teriparatide treatment in patients with osteoporosis

Rizzoli, R; Kraenzlin, M; Krieg, M A; Mellinghoff, H U; Lamy, O; Lippuner, K (2011). Indications to teriparatide treatment in patients with osteoporosis. Swiss medical weekly, 141, w13297. Muttenz: EMH Schweizerischer Ärzteverlag 10.4414/smw.2011.13297

Full text not available from this repository. (Request a copy)

To prevent osteoporotic fracture occurrence, a variety of treatment regimens with different mechanisms of action is available. The antiresorptive bisphosphonate drugs are currently the most commonly prescribed agents in the management of patients with osteoporosis. The recombinant amino-terminal fragment of human parathyroid hormone (Teriparatide) is a bone anabolic agent which reduces fracture risk by increasing bone mass and improving bone microarchitecture. Teriparatide treatment reduces vertebral and non-vertebral fracture risk markedly in women and men with idiopathic osteoporosis, or with glucocorticoid-induced osteoporosis. Teriparatide should thus be considered as first line treatment for postmenopausal women and for men with severe osteoporosis.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Orthopaedic, Plastic and Hand Surgery (DOPH) > Clinic of Osteoporosis

UniBE Contributor:

Lippuner, Kurt

ISSN:

1424-7860

Publisher:

EMH Schweizerischer Ärzteverlag

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:21

Last Modified:

06 Dec 2013 13:27

Publisher DOI:

10.4414/smw.2011.13297

PubMed ID:

22057669

Web of Science ID:

000296731300001

URI:

https://boris.unibe.ch/id/eprint/6913 (FactScience: 211985)

Actions (login required)

Edit item Edit item
Provide Feedback